Samsung-backed Element showcases next-gen DNA sequencing tech in Seoul

What happened: Element Biosciences, backed by Samsung Electronics as its largest shareholder, began a global road show in Seoul on Tuesday to showcase its DNA sequencing and multiomics technologies, including the Vitari sequencer and Cytos platform. Key Why it matters: Element says Cytos lets researchers track how cells respond to drug treatments and better understand disease mechanisms, potentially accelerating drug discovery. The Seoul event features researchers from Samsung Medical Center, KAIST, Yonsei University College of Medicine and institutions in Japan, Australia and India.

Element Biosciences, backed by Samsung Electronics as its largest shareholder, began a global road show in Seoul on Tuesday to showcase its DNA sequencing and multiomics technologies, including the Vitari sequencer and Cytos platform. Key

Element says Cytos lets researchers track how cells respond to drug treatments and better understand disease mechanisms, potentially accelerating drug discovery. The Seoul event features researchers from Samsung Medical Center, KAIST, Yonsei University College of Medicine and institutions in Japan, Australia and India.